Dorzolamide-timolol reduces IOP better than brimonidine after phaco

Article

Prophylactic treatment with dorzolamide-timolol fixed combination is more effective than brimonidine in reducing IOP after phacoemulsification surgery, claims a study published in the January issue of Eye & Contact Lens: Science & Clinical Practice.

Prophylactic treatment with dorzolamide-timolol fixed combination is more effective than brimonidine in reducing IOP after phacoemulsification surgery, claims a study published in the January issue of Eye & Contact Lens: Science & Clinical Practice.

Yelda Ozkurt, MD and team at the Kartal Training and Research Hospital, Turkey performed a prospective, randomized study to compare the effects of dorzolamide-timolol combination and brimonidine on intraocular pressure (IOP) after phaco.

The study included 69 eyes of 43 patients undergoing phacoemulsification and foldable IOL implantation. Patients were randomly assigned to one of three treatment groups preoperatively; group A (n=23) received one drop of dorzolamide-timolol fixed combination and group B (n=23) received one drop of brimonidine tartrate 0.2% immediately after surgery. Group C (n=23), in which patients received no treatment, was the control group. IOP was measured by Goldmann applanation tonometry six and 24 hours after surgery.

Six hours after surgery, the mean IOP was significantly lower in group A (16.3±2.9 mmHg) than in groups B (20.6±2.9 mmHg) and C (24.6±5.4 mmHg). Twenty-four hours after surgery, the mean IOP remained lowest in group A (14.1±2.8 mmHg) and was higher in group C (19.8±4.7 mmHg) than in group B (17.5±2.7 mmHg).

The researchers therefore demonstrated that prophylactic treatment with dorzolamide-timolol fixed combination was more effective than brimonidine in reducing IOP six hours and 24 hours after cataract surgery.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.